Skip to main content

Table 5 Microbiologic response by patient at test-of-cure visit (ME population)

From: Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial

  Tigecycline Imipenem/cilastatin Difference (Tigecycline-Imipenem/cilastatin)
  N % (95% CI) N % (95% CI) % (95% CI)
Overall      
   Eradication 45/52 86.5
(74.2, 94.4)
47/48 97.9
(88.9, 99.9)
-11.4
(-23.5, 0.7)
   Persistence 7/52 13.5
(5.6, 25.8)
1/48 2.1
(0.1, 11.1)
 
   Superinfection 0/52 0
(0.0, 6.8)
0/48 0
(0.0, 7.4)
 
Monomicrobial      
   Eradication 30/33 90.9
(75.7, 98.1)
25/26 96.2
(80.4, 99.9)
-5.2
(-22.0, 13.7)
   Persistence 3/33 9.1
(1.9, 24.3)
1/26 3.8
(0.1, 19.6)
 
   Superinfection 0/33 0
(0.0, 10.6)
0/26 0
(0.0, 13.2)
 
Polymicrobial      
   Eradication 15/19 78.9
(54.4, 93.9)
22/22 100.0
(84.6, 100.0)
-21.1
(-46.1, 2.2)
   Persistence 4/19 21.1
(6.1, 45.6)
0/22 0
(0.0, 15.4)
 
   Superinfection 0/19 0
(0.0, 17.6)
0/22 0
(0.0, 15.4)